Evidence map›Paper›PMID 40960295›Full record

ArticleJournal of virology2025

Identification of clinical and virological correlates associated with influenza A candidate vaccine virus (CVV) attenuation in a ferret model.

Claudia Pappas, Nicole Brock, Jessica A Belser, Troy J Kieran, Joanna A Pulit-Penaloza, Xiangjie Sun, Hui Zeng, Li Wang, Bin Zhou, Terrence M Tumpey and 1 more

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Claudia PappasInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0003-1867-1147
Nicole BrockInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jessica A BelserInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-0755-7368
Troy J KieranInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-3711-0727
Joanna A Pulit-PenalozaInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Xiangjie SunInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-9872-1337
Hui ZengInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-0180-7493
Li WangInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Bin ZhouInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Terrence M TumpeyInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Taronna R MainesInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-4097-6724

Funding

CDC HHS
6 · The paper itself

Abstract

Influenza A viruses continuously circulate among avian and swine species, posing a persistent threat to public health. The development of influenza candidate vaccine viruses (CVVs) plays a pivotal role in the global strategy for influenza pandemic preparedness. Safety-testing of CVVs for attenuation in ferrets represents a critical step that takes place prior to making these viruses available to vaccine manufacturers. Development of pathogenicity standards is needed to establish acceptable thresholds of disease so that CVV safety can be assessed without the need for comparison to the parental virus. To assess the capacity of diverse CVVs to cause pathogenesis in mammalian hosts, clinical and virological parameters were compiled from CVV assessments in ferrets conducted using consistent methods over approximately 20 years to identify disease parameters most reflective of attenuation compared to wild-type strains. These analyses revealed an overall reduction in ferret weight loss and fever relative to wild-type controls. Viral titers in nasal washes were reduced with limited spread to tissues beyond the respiratory tract. Regression models further support the significance of clinical signs in distinguishing the virulence of wild-type viruses and CVVs. These findings provide support for the development of standardized parameters for assessing pathogenicity of CVVs and their suitability for manufacturers. IMPORTANCE: The development and safety testing of candidate vaccine viruses (CVVs) against emerging zoonotic influenza strains prior to sharing with vaccine manufacturers is a critical component of influenza pandemic preparedness. The extensive data set reported here provides critical information that will drastically streamline the safety testing process, thereby enabling more efficient CVV assessments and improving public health in the event of an influenza pandemic.

Indexed as

Influenza A virusInfluenza VaccinesOrthomyxoviridae InfectionsAnimalsDisease Models, AnimalFemaleFerretsHumansVaccines, AttenuatedViral LoadInfluenza VaccinesVaccines, Attenuatedcandidate vaccine virusferretszoonotic influenza virus

Identifiers

PMID40960295
PMCPMC12548434

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.